Skip to main content
. Author manuscript; available in PMC: 2014 Nov 4.
Published in final edited form as: J Clin Oncol Res. 2014 Jan 15;2(1):http://www.jscimedcentral.com/Oncology/oncology-2-1004.php.

Figure 1.

Figure 1

VorinostatSAHA promotes HRS in D54 but not U118 cells. A) Clonogenic survival assay measured in D54 cells after radiation followed by exposure to VorinostatSAHA (1.5 μM) for 4hr. Relative survival of cells exposed to radiation (RAD) is expressed as a percentage of the untreated cells or cells treated with VorinostatSAHA alone (RAD/SAHA). B) U118 cells treated as in A). Broken line is a graph of the linear quadratic equation with best-fit parameters calculated by SigmaPlot software. C) Radiation Enhancement Ratio (RER) by HDACI calculated with the following formula; RER= Surviving Fractionradiation alone/Surviving Fractionradiation + HDACI. D) Apoptosis assay. Caspase-3 activity was measured in D54 cells 72 hrs after the indicated radiation treatment followed by 4hr of VorinostatSAHA (1.5 μM). * = p<0.05 as compared to radiation alone. † = p<0.05 as compared to surviving fraction predicted by the linear quadratic model.